Ana del Carmen García-González

Ana del Carmen García-González

Auto-generated profile, based on publicly available information

Ana del Carmen García-González

Secretaría de Salud, Hospital General de México, Servicio de Inmunología Clínica y Alergia, Ciudad de México

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2018 in Revista Alergia México
Verified
Journal Article
Open access
PDF file
MAMariana Esther Arroyo-Cruz
Mariana Esther Arroyo-Cruz
RCRodrigo Collado-Chagoya
Rodrigo Collado-Chagoya
JHJavier Hernández-Romero
Javier Hernández-Romero
AAAlejandro Eliosa Alvarado-Gumaro
Alejandro Eliosa Alvarado-Gumaro
AGAna del Carmen García-González
Ana del Carmen García-González
GVGuillermo Velázquez-Sámano
Guillermo Velázquez-Sámano
Background: The prevalence of latex allergy ranges from 0.8 to 6.5% and is the second cause of perioperative anaphylaxis. The main risk factors are being a health worker or latex producer, hours of latex gloves or products usage, exposure to other hand irritants, history of atopy, neural tube closure defects or numerous surgeries at early age.Objective: To determine the frequency of latex sensitization in resident physicians of the Hospital General de México surgical area.Methods: Prospective, cross-sectional, descriptive study where skin prick tests were applied to residents of the surgical area of the Hospital General de México, which depends on the Ministry of Health and is located in Mexico City.Results: Ninety-two subjects were included and had skin tests practiced, with 11 surgical specialties participating. Latex sensitization in this population was 11.9%, whereas the presence of latex allergy was 10.8%.Conclusions: A high frequency of latex sensitization and allergy was demonstrated in Hospital General de Mexico surgery residents, which indicates the need for policies and procedures to be developed for health workers with latex allergy, as well as continuous training of employees on latex allergy.

21 January 2021 in Revista Alergia México
Verified
Journal Article
Open access
SASaid Eduardo Arablin-Oropeza
Said Eduardo Arablin-Oropeza
VGVictor Gonzalez-Uribe
Victor Gonzalez-Uribe
BRBlanca Estela Del Rio-Navarro
Blanca Estela Del Rio-Navarro
AGAna del Carmen García-González
Ana del Carmen García-González
ENElsy Maureen Navarrete-Rodríguez
Elsy Maureen Navarrete-Rodríguez
AVAlberto Valencia
Alberto Valencia
Dupilumab is a fully human monoclonal antibody against the interleukin (IL)-4 and IL-4/IL-13 receptor complexes. These are key cytokines in driving type 2 inflammation, a dominant and largely inflammatory pathway in asthma. Trials evaluating the efficacy of dupilumab in asthma include three pivotal, placebo-controlled, phase 2b or 3 trials of 24-52 weeks treatment duration in patients aged below 12 years with moderate-to severe asthma (inadequately controlled with medium-to-high dose inhaled corticosteroids) or severe asthma (dependent on oral corticosteroids for control). In these studies, adding subcutaneous dupilumab to background therapy was generally well tolerated and reduced the rate of severe asthma exacerbations, improved lung function, as well as asthma control and, health-related quality of life, and enabled oral corticosteroids maintenance doses to be reduced without impacting asthma control. Dupilumab displayed efficacy across various patient subgroups, although those with heightened type 2 immune activity, tended to have a more prominent treatment benefit. Dupilumab is consequently widely indicated (and a valuable treatment option) as an add-on therapy in patients aged below 12 years who have severe/moderate-to-severe asthma with a type 2 inflammation/eosinophilic phenotype despite conventional treatments or have oral corticosteroids-dependent asthma.

10 April 2018 in Revista Alergia México
Verified
Journal Article
Open access
PDF file
RCRodrigo Collado-Chagoya
Rodrigo Collado-Chagoya
JHJavier Hernández-Romero
Javier Hernández-Romero
GEGumaro Alejandro Eliosa-Alvarado
Gumaro Alejandro Eliosa-Alvarado
AGAna del Carmen García-González
Ana del Carmen García-González
RCRosa Isela Campos-Gutiérrez
Rosa Isela Campos-Gutiérrez
GVGuillermo Velázquez-Sámano
Guillermo Velázquez-Sámano
Background: Psyllium is a derivative of Plantago ovata ground seed and husk that is used as bulk-forming laxatives owing to its hydrocolloid properties.Case report: 43-year-old female nurse with previous diagnosis of drug allergy and allergic rhinitis who, after the preparation and administration of a laxative, developed rhinoconjunctivitis symptoms, urticarial syndrome, angioedema and bronchospasm, which led to conclude that she had an anaphylactic reaction. She was treated with adrenaline, corticosteroids and antihistamines. After symptom resolution, with in vivo tests by means of the skin prick technique and by in vitro assay (specific IgE), hypersensitivity to plantago psyllium was determined.Discussion: Most cases of anaphylaxis have been reported with psyllium ingestion, since, through that route, antigenic burden is higher. It should be noted that, even when exposure in the described patient was only by inhalation, manifestations were life-threatening.

30 July 2018 in Revista Alergia México
Verified
Journal Article
Open access
PDF file
RCRodrigo Collado-Chagoya
Rodrigo Collado-Chagoya
JHJavier Hernández-Romero
Javier Hernández-Romero
GEGumaro Alejandro Eliosa-Alvarado
Gumaro Alejandro Eliosa-Alvarado
AGAna del Carmen García-González
Ana del Carmen García-González
RCRosa Isela Campos-Gutiérrez
Rosa Isela Campos-Gutiérrez
GVGuillermo Velázquez-Sámano
Guillermo Velázquez-Sámano
Background: Rhinitis is the leading cause for consultation in the allergy department. It consists in chronic inflammation of the nasal mucosa. Non-allergic rhinitis with eosinophilic syndrome is characterized by chronic inflammation of the nasal mucosa (> 20% of eosinophils in nasal cytology) in the absence of demonstrable allergy (negative in vivo and in vitro tests); often it is accompanied by other sinonasal conditions (nasal polyposis, chronic rhinosinusitis), and it constitutes a risk factor for the development of obstructive sleep apnea.Clinical case: Seven-year old girl with rhinorrhea, nasal obstruction, nasopalatine itching, and severe sneezing that limited sleep and school activities. This condition had a seasonal pattern, with important blood (800 eosinophils/μL) and nasal (30%) eosinophilia and absence of demonstrable allergy (negative skin tests, negative specific nasal challenge tests); the non-allergic rhinitis with eosinophilic syndrome diagnosis was verified.Conclusions: Non-allergic rhinitis with eosinophilic syndrome is considered to be a highly underdiagnosed disease owing to the lack of in vivo nasal tests’ performance; to this underestimation, incorrect nasal etiology and lack of local in vivo tests (nasal specific IgE) are added, which warrants a high degree of diagnostic suspicion by the specialist physician.